ePrints

In Vivo Pretargeted Imaging of HER2 and TAG-72 Expression Using the HaloTag Enzyme

Lookup NU author(s): Dr James KnightORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© 2017 American Chemical Society. A novel pretargeted SPECT imaging strategy based on the HaloTag enzyme has been evaluated for the first time in a living system. To determine the efficacy of this approach, two clinically relevant cancer biomarkers, HER2 and TAG-72, were selected to represent models of internalizing and noninternalizing antigens, respectively. In MDA-MB-231/H2N (HER2-expressing) and LS174T (TAG-72-expressing) xenograft tumors in mice, pretargeting experiments were performed in which HaloTag-conjugated derivatives of the antibodies trastuzumab (anti-HER2) or CC49 (anti-TAG-72) were utilized as primary agents, and the small molecule HaloTag ligands 111In-HTL-1, -2, and -3 were evaluated as secondary agents. While this approach was not sufficiently sensitive to detect the internalizing HER2 antigen, pretargeting experiments involving the most optimal secondary agent, 111In-HTL-3, were successful in detecting the noninternalizing antigen TAG-72 and provided high-contrast SPECT images at 4 and 24 h postinjection.

Publication metadata

Author(s): Knight JC, Mosley M, Uyeda HT, Cong M, Fan F, Faulkner S, Cornelissen B

Publication type: Article

Publication status: Published

Journal: Molecular Pharmaceutics

Year: 2017

Volume: 14

Issue: 7

Pages: 2307-2313

Print publication date: 03/07/2017

Online publication date: 15/05/2017

Acceptance date: 15/05/2017

Date deposited: 30/08/2018

ISSN (print): 1543-8384

ISSN (electronic): 1543-8392

Publisher: American Chemical Society

URL: https://doi.org/10.1021/acs.molpharmaceut.7b00172

DOI: 10.1021/acs.molpharmaceut.7b00172

PubMed id: 28505463

Altmetrics

Share